CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You?

Healthcare and telemedicine stocks have delivered some of the market’s biggest winners in recent years, as investors bet on the growing demand for virtual care, wellness, and weight-loss solutions. Companies like Hims & Hers Health (HIMS) became investor favorites thanks to their aggressive expansion into telehealth and new treatment categories, including the booming GLP-1 weight-loss market. However, the narrative took a sharp turn this week after CEO Andrew Dudum sold about $11 million worth of stock, s ...